CA2626728A1 - Mntf differentiation and growth of stem cells - Google Patents

Mntf differentiation and growth of stem cells Download PDF

Info

Publication number
CA2626728A1
CA2626728A1 CA002626728A CA2626728A CA2626728A1 CA 2626728 A1 CA2626728 A1 CA 2626728A1 CA 002626728 A CA002626728 A CA 002626728A CA 2626728 A CA2626728 A CA 2626728A CA 2626728 A1 CA2626728 A1 CA 2626728A1
Authority
CA
Canada
Prior art keywords
mntf
cells
analogue
cell
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002626728A
Other languages
English (en)
French (fr)
Inventor
Deepa M. Deshpande
Douglas A. Kerr
Pui-Yuk Dorothy Ko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genervon Biopharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2626728A1 publication Critical patent/CA2626728A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002626728A 2005-11-10 2006-11-10 Mntf differentiation and growth of stem cells Abandoned CA2626728A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US73570205P 2005-11-10 2005-11-10
US60/735,702 2005-11-10
US84176606P 2006-09-01 2006-09-01
US60/841,766 2006-09-01
US85802206P 2006-11-10 2006-11-10
US60/858,022 2006-11-10
PCT/US2006/043874 WO2007058982A2 (en) 2005-11-10 2006-11-10 Mntf differentiation and growth of stem cells

Publications (1)

Publication Number Publication Date
CA2626728A1 true CA2626728A1 (en) 2007-05-24

Family

ID=38049179

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002626728A Abandoned CA2626728A1 (en) 2005-11-10 2006-11-10 Mntf differentiation and growth of stem cells

Country Status (7)

Country Link
US (1) US8986676B2 (https=)
EP (1) EP1965826B1 (https=)
JP (2) JP5270362B2 (https=)
CN (1) CN101374537B (https=)
AU (1) AU2006315668B2 (https=)
CA (1) CA2626728A1 (https=)
WO (1) WO2007058982A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069713A1 (en) * 2018-05-11 2021-03-11 Georgia Tech Research Corporation Systems and Methods for Electronic Surface Antigen Expression Analysis Using Magnetophoresis

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2028268A1 (en) 2007-08-20 2009-02-25 Université Libre De Bruxelles Generation of neuronal cells from pluripotent stem cells
ES2569552T3 (es) * 2008-02-21 2016-05-11 Genervon Biopharmaceuticals Llc Composiciones de péptido de MNTF y métodos de uso
US20120142005A1 (en) * 2009-05-26 2012-06-07 Takeda Pharmaceutical Company Limited Method for screening of regenerative medicine
WO2013025963A2 (en) 2011-08-17 2013-02-21 President And Fellows Of Harvard College Conversion of somatic cells into functional spinal motor neurons, and methods and uses thereof
PT2773748T (pt) * 2011-11-04 2020-03-26 Memorial Sloan Kettering Cancer Center Neurónios dopaminérgicos (da) do mesencéfalo para enxerto
CN104073468B (zh) * 2014-07-16 2016-04-27 栾佐 获得人源OPCs的方法和OPCs培养基
US11427808B2 (en) 2014-11-14 2022-08-30 Regenesis Science Co., Ltd. Method for serum-free culture of chondrocytes and serum-free culture medium
WO2016210123A1 (en) 2015-06-26 2016-12-29 Genervon Biopharmaceuticals, LLC Methods of using gm604 in modulating als disease biomarkers leading to prognosis and therapeutic treatment for als disease
WO2018119018A1 (en) * 2016-12-23 2018-06-28 Genervon Biopharmaceuticals, LLC Methods of using gm6 in diagnosing and treating alzheimer's disease
CN118853569B (zh) * 2024-09-29 2025-03-04 星奕昂(上海)生物科技有限公司 一种拟胚体消化液及其在分离造血干细胞中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6309877B1 (en) 1996-09-27 2001-10-30 Km Biotech, Inc. Polynucleotides encoding motoneuronotrophic factors
US6841531B2 (en) * 1996-09-27 2005-01-11 Genervon Biopharmaceuticals Llc Methods and use of motoneuronotrophic factors
US6300117B1 (en) 1997-09-15 2001-10-09 Genencor International, Inc. Proteases from gram-positive organisms
JP5943533B2 (ja) 2000-05-17 2016-07-06 アステリアス バイオセラピューティクス インコーポレイテッド 神経前駆細胞の集団
US7390659B2 (en) * 2002-07-16 2008-06-24 The Trustees Of Columbia University In The City Of New York Methods for inducing differentiation of embryonic stem cells and uses thereof
ES2375797T3 (es) * 2003-01-21 2012-03-06 Genervon Biopharmaceuticals Llc Péptidos y compuestos de factores tróficos de motoneuronas y sus procedimientos de utilización.
CA2544347A1 (en) * 2003-11-07 2005-05-26 Genervon Biopharmaceuticals Llc Motoneuronotrophic factor gene sequences

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069713A1 (en) * 2018-05-11 2021-03-11 Georgia Tech Research Corporation Systems and Methods for Electronic Surface Antigen Expression Analysis Using Magnetophoresis
US12364985B2 (en) * 2018-05-11 2025-07-22 Georgia Tech Research Corporation Systems and methods for electronic surface antigen expression analysis using magnetophoresis

Also Published As

Publication number Publication date
JP5270362B2 (ja) 2013-08-21
JP2009515891A (ja) 2009-04-16
AU2006315668A1 (en) 2007-05-24
CN101374537A (zh) 2009-02-25
CN101374537B (zh) 2016-04-20
US20090117085A1 (en) 2009-05-07
JP2013177388A (ja) 2013-09-09
AU2006315668B2 (en) 2013-06-20
EP1965826B1 (en) 2014-12-31
WO2007058982A3 (en) 2008-09-25
HK1125824A1 (zh) 2009-08-21
EP1965826A4 (en) 2010-08-25
EP1965826A2 (en) 2008-09-10
US8986676B2 (en) 2015-03-24
WO2007058982A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
JP2013177388A (ja) 幹細胞のｍｎｔｆ分化および成長
AU2003273615B2 (en) Neuroprotective synergy of erythropoietin and insulin-like growth factor
AU2007317730B2 (en) Methods of treating neuronal disorders using MNTF peptides and analogs thereof
CA2716392C (en) Mntf peptide compositions and methods of use
AU2008289209A1 (en) Methods for promoting stem cell proliferation and survival
HK1125824B (en) Mntf differentiation and growth of stem cells
HK1137623B (en) Methods of treating neuronal disorders using mntf peptides and analogs thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20220215